Drug discovery biotech looking into the ‘dark’ regions of the human genome picks up a $40M+ Series A
While the combo of machine learning and drug discovery has managed to rake in a lot of capital for companies this year, one biotech is looking to the dark side of the genome to stand out.
Nucleome Therapeutics, a UK-based company founded in 2019 and spun off from Oxford University, is seeking to create precision medicines by decoding “dark matter” from the human genome to find targets no one else has gone after. The company has now garnered a £37.5 million ($42.4 million) Series A to advance its disease programs and build out its platform.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.